Hemolytic-uremic syndrome due to gemcitabine
10.3760/cma.j.issn.1008-5734.2019.01.011
- VernacularTitle:吉西他滨致溶血性尿毒症综合征
- Author:
Xuejia QIU
1
;
Difei YAO
;
Zhanjun DONG
Author Information
1. 河北省人民医院药学部,石家庄,050051
- Publication Type:Journal Article
- Keywords:
Hemolytic-uremic syndrome;
Gemcitabine
- From:
Adverse Drug Reactions Journal
2019;21(1):57-58
- CountryChina
- Language:Chinese
-
Abstract:
A 25-year-old male patient with epithelioid hemangioendothelioma received periodic chemotherapy with gemcitabine 1600 mg (on day 1 and 8 of each chemotherapy cycle)and docetaxel 110 mg (on day 8 of each chemotherapy cycle)and the chemotherapy cycle was 21 days. The patient developed fever on day 7 after the first IV infusion of gemcitabine in the third chemotherapy cycle and then the following infusions of this cycle was abandoned. Thirty days later,he was hospitalized in the Second Affiliated Hospital of Zhejiang University School of Medicine to undergo the fourth chemotherapy cycle. On day 4 after hospitalization,the patient developed urinary incontinence and 900 ml of soy sauce-colored liquid was drained by catheter. Laboratory tests showed red blood cell count 2. 19 × 1012 / L,hemoglobin 63 g/ L, and platelet 257 × 109 / L. The patient was diagnosed as hemolytic-uremic syndrome due to gemcitabine. The patient′s condition improved after Ⅳ infusions of alprostadil injection,reduced glutathione for injection,and suspended red blood cells for 6 days.
